on Core One Labs Inc. (isin : CA21872J3073)
Core One Labs Enters into Loan Agreement with Right Season Investments
Vancouver, BC - Core One Labs Inc. (CSE:COOL, OTCQB:CLABF, Frankfurt:LD6) has announced a loan agreement with Right Season Investments Corp. The agreement was finalized on June 28, 2024, and involves a loan of CDN$300,000. This loan is repayable upon demand and carries an annual interest rate of 15%.
The funds from the loan will be used for general administrative and working capital expenses. Core One Labs specializes in psychedelic medicines, focusing on developing and producing psychedelic compounds and treatments.
Core One operates a multi-faceted business model within the psychedelics market. It has developed and filed for patent protection on a psilocybin production system using engineered bacteria through its subsidiary Vocan Biotechnologies Inc. Additionally, it has four provisional patents targeting neurological and mental health disorders.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Core One Labs Inc. news